Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

No Link Found Between LCIS and Local Recurrence

February 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

BOSTON-Neither the presence nor the extent of lobular carcinoma in situ (LCIS) is related to risk of local recurrence in patients with invasive breast cancer treated with conservative surgery and radiotherapy, a retrospective study from the Joint Center for Radiation Therapy has shown.

BOSTON—Neither the presence nor the extent of lobular carcinoma insitu (LCIS) is related to risk of local recurrence in patients with invasivebreast cancer treated with conservative surgery and radiotherapy, a retrospectivestudy from the Joint Center for Radiation Therapy has shown.

"This is very different from the situation with associated DCIS,"Stuart Schnitt, MD, said at a general session. Joint Center data show thatinfiltrating ductal carcinoma with a large amount of associated DCIS hasa five-year local recurrence rate of 24% vs 6% when there is little orno DCIS.

The LCIS study included 858 patients with clinical stage I or II infiltratingductal carcinoma (782 patients), infiltrating lobular carcinoma (44 patients),or infiltrating carcinoma with mixed ductal and lobular features (32 patients),treated with conservative surgery and radiotherapy.

Overall, neither local recurrence nor the incidence of distant failurewas related to histologic type. In terms of LCIS, 4% of patients with infiltratingductal cancer had associated LCIS. Not surprisingly, the vast majority(93%) of patients with infiltrating lobular carcinoma had associated LCIS.Of the patients with mixed ductal/lobular features, 59% had associatedLCIS.

Other prognostic factors for local recurrence were equally distributedamong the three groups and among those with and without LCIS. The mostimportant prognostic factor, margin status, was unknown in most patients.

The investigators then looked at the 10-year crude rate of local recurrenceamong patients with and without LCIS. Patients with infiltrating ductalcarcinoma and no LCIS had a local recurrence rate of 14% vs 10% for thosefew patients in whom LCIS was present. Among infiltrating lobular carcinomas,there were no local recurrences in the three patients without LCIS, andfive (12%) among the patients with LCIS.

For patients with mixed features, local recurrence was 15% with no LCIS,and 16% with LCIS. None of these differences were significant. Similarly,the extent of LCIS was not associated with the risk of local recurrencein any group. Based on these results, Dr. Schnitt suggests that the presenceof associated LCIS should not influence local management of infiltratingductal, lobular, or mixed carcinoma.

Articles in this issue

NCI Launches Trial of High-Dose Chemo for Advanced Ovarian Cancer
Brachytherapy to Tumor Bed After Lumpectomy a Possible Alternative to External Beam Therapy
Breast Conservation Is Contraindicated in Less Than 25% of Early-Stage Patients
'More May Be Less' in Metastatic Cervical Cancer
At 10 Years, DCIS Patients' Risk of Breast Cancer Death Is Very Low
Tumor Cells in Marrow May Better Predict Metastases Than Axillary Node Dissection
Survey Finds 122 New Anti-HIV Medicines Currently Being Tested
Delaying Radiotherapy to Allow Adjuvant Chemotherapy Not Shown to Increase Ipsilateral Recurrence Risk
President Clinton Unveils National AIDS Policy
Mammotomy May Reduce Biopsy Sampling Errors
Ultrasound Advances May Expand Role in Treatment Planning
Bills to Regulate Managed Care Are Introduced
NIH Consensus Development Statement Sparks Rancor
Breast Cancer Patients May Overestimate the Benefits of Adjuvant Chemotherapy
Letrozole Superior to Progestin as Second-Line Postmenopausal Advanced Breast Cancer Therapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article


TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

Radhika Appaya;Debasish Tripathy;Dejan Juric;Sonia Pernas;Francois Clement Bidard;Kevin Perraud;Louise Emmett;Ana Sofia Ferreira
June 22nd 2025
Article

Related Content

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article


TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

Radhika Appaya;Debasish Tripathy;Dejan Juric;Sonia Pernas;Francois Clement Bidard;Kevin Perraud;Louise Emmett;Ana Sofia Ferreira
June 22nd 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.